Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 4/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL4340806 | 0.97 | P2RY2 (0.32) | P2RY6P2RY2P2RY4 | |
| SCHEMBL5960168 | 0.82 | P2RY14 (0.33) | P2RY6P2RY2P2RY4 | |
| SCHEMBL8205228 | 0.80 | DUT (0.32) | P2RY6P2RY2P2RY4 | |
| SCHEMBL9218584 | 0.77 | P2RY2 (0.40) | P2RY6P2RY2P2RY4 | |
| SCHEMBL8210900 | 0.75 | P2RY2 (0.33) | P2RY6P2RY2 | |
| SCHEMBL10647168 | 0.74 | TK1 (0.31) | — | |
| SCHEMBL10644742 | 0.74 | — | — | |
| SCHEMBL10643490 | 0.74 | — | — | |
| SCHEMBL10645242 | 0.74 | — | — | |
| SCHEMBL10646812 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677822-B1 | 4'-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20050130923-A1 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | IONIS PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | SNRPE, NSUN3, NSUN2 | P2RY6 4305/4885P2RY2 4546/4885P2RY4 4444/4885 |
| US-20050130923-A1 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | NSUN2, SNRPE, SNRPA | P2RY6 3954/4885P2RY2 4211/4885P2RY4 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.